Day 1 :
Carla Natalucci-Hall, Psy.D, USA
Carla Natalucci-Hall, Psy.D. is an EMDR certified therapist & Consultant that has developed a therapeutic system to successfully address A.D.H.D. effectively. In her clinical practice, she has dealt with children & adolescents with A.D.H.D. for over 20 years & has had significant success with students improving daily accountability and completing classes on time with solid grades. Dr. Natalucci-Hall & Matt Starr have also created a unique online program for behavioral health care professionals to learn the current program to develop the skills to help individuals with A.D.D. and A.D.H.D.
Statement of the problem: Individuals, both diagnosed and undiagnosed, with A.D.H.D. or A.D.D. (Attention Deficit Disorder with and without Hyperactivity), have unique challenges in negotiating daily experiences as well as developmental transitions. Our research seeks to explain how throughout these normative challenges, there is an accumulation of small t traumas that begin to impinge upon the individual causing anxiety, negative mood and feelings about oneself as “not good enough”. Difficulty with persistence as well as focused attention has led many individuals with A.D.H.D. or A.D.D. to drop out of weekly CBT (CognitiveBehavioral) psychotherapy and, thus, not progress in the use of skills and strategies that have been shown through research to be helpful with these symptoms. To increase the possibility of helping the community of people with A.D.D.or A.D.H.D., we have developed a protocol using EMDR (Eye Movement Desensitization & Reprocessing Therapy) to address small t traumas. In addition to the homeopathic use of Omega-3, video games, group therapy and parent training were integrated into the overall treatment protocol. Results from our first group of 9 subjects have produced positive and promising results. These include: increased levels of self-esteem, higher levels of concentration producing more adaptive interpersonal experiences and
academic performance, less reactivity in daily activities and more support from parents and teachers as a result. Researchers are in the process of developing an online class for behavioral health professionals, which would communicate our findings and provide training for including the elements of our program in their therapeutic sessions. They are also working toward developing a class for college students and their parents to prepare for that specific life transition with A.D.D.or A.D.H.D.
Polish Academy of Sciences, Poland
Beata Orzechowska has her research on understanding the innate immune system activation and regulation. Currently, she is working as a scientist at the Ludwick Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Science in Wroclaw, Poland. In her research she studies antiviral activity of natural products with a special focus on their impact on viral attachment, entry processes and inhibition of viral replication.
B-Acute Lymphoblastic Leukemia (B-ALL) is a neoplasm of immature B-cell precursors. B-ALL is the most prevalent hematological malignancy in children. Characteristic translocations in B-ALL include: t (9;22) [BCR-ABL1], t (12;21) [ETV6-RUNX1], t (1;19) [TCF3-PBX1] and rearrangement of the mixed-lineage leukemia 1 (MLL1) gene. MLL1 on chromosome 11q23 has been shown to generate in-frame fusions to more than 80 different partner genes, although the majority of leukemias result from MLL1 fusions with one of about six common partner genes. MLL rearrangements occur in over 70% of infant B-ALLs and are less frequent in older patients. The t (1; 19) (q23; p13) is also one of the most frequent translocations in B-ALLs and is observed in both adult and pediatric populations at an overall frequency of 6%. This translocation can result in the fusion of TCF3 (Transcription Factor 3) found at 19p13 and PBX1 (Pre-B Cell Leukemia Homebox1) found at 1q23 to form a chimeric gene whose protein product alters cell differentiation arrest, among other cellular processes. B-ALLs with MLL gene rearrangements and translocation t (1; 19) (q23; p13.3) are usually associated with a very poor prognosis. Here we showed that baicalin which is the main component of the extract from the root of skullcap (Scutellaria baicalensis Extract-SBE) possess antitumor activity against three human B-ALL cell lines with MLL rearrangement: KOPN-8-with t (11; 19) (q23; p13)/MLL-ENL fusion gene, RS4;11 and SEM cell lines with t(4; 11)(p21; q23)/MLL/AF4 fusion gene, and one cell line with (1; 19) translocation involving TCF3-PBX1 fusion-RCH-ACV-t(1; 19)(q23; p13.3). SBE inhibited proliferation of cell lines and increased activities of caspase-3 and -7 without affecting normal human B cell line or Peripheral Blood Leukocytes (PBLs) obtained from healthy control individuals or normal human leukocytes. Furthermore, flow cytometric analysis of SBE-treated cells showed G0/G1 phase cell cycle arrest in tumor cell lines.